Aldeyra Therapeutics, Inc. beat EPS estimates 100% of the time across 3 reported quarters (3 beats, 0 misses), averaging +31.1% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.11 | $-0.09 | +18.2% | Beat | |
| Q1 FY26 | $-0.13 | $-0.06 | +53.9% | Beat | |
| Q4 FY25 | $-0.14 | $-0.11 | +21.4% | Beat |
Back to ALDX overview · ALDX holders · ALDX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.